TYK151: Difference between revisions
No edit summary |
m Text replacement - "<p style="text-align: center;"> About Test Your Knowledge</p>" to "<p style="text-align: center;"> About Test Your Knowledge</p> Category:TYK" |
||
| (One intermediate revision by the same user not shown) | |||
| Line 41: | Line 41: | ||
<p style="text-align: center;">[[TYK150|<Prev Question]] --- [[TYK152|Next Question>]]</p> | <p style="text-align: center;">[[TYK150|<Prev Question]] --- [[TYK152|Next Question>]]</p> | ||
<p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | <p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | ||
[[Category:TYK]] | |||
Latest revision as of 02:29, 25 September 2026
Verapamil should not be given for the treatment of SVT in patients with Wolff- Parkinson-White syndrome because:
a) It has not been shown to be effective at terminating SVT in these patients
b) It can precipitate ventricular tachydysrhythmias in these patients
c) Its onset of action is delayed in patients with WPW
d) Reflex tachycardia and decreased afterload may lead to hypertensive crisis
e) Verapamil is NOT contraindicated in patients with WPW
Click for Answer
Answer
Answer b.
Verapamil is effective at terminating SVT in older children and adults, but may precipitate ventricular tachydysrhythmias in patients with Wolf- Parkinson-White syndrome.
Notes
- This question originally printed in the Pediatric Anesthesiology Review Topics kindle book series, and appears courtesy of Naerthwyn Press, LLC.
Keywords